Seer Medical revived with $40M funding for at-home epilepsy monitoring
Summary
Seer Medical has been revived with a $40 million investment from neurodiagnostic equipment manufacturer Cadwell Industries, existing investor Breakthrough Victoria, and Singapore's TrialCap. The Melbourne-based medtech startup's technology enables clinical monitoring at home for epilepsy diagnostics and management, including at-home video EEG monitoring designed to enable high-quality, long-term studies without hospitalization.
Why it matters
Seer Medical's revival represents a significant turnaround after the company entered voluntary administration in early 2025. With over 50 million people with epilepsy worldwide, including more than 3 million in the US, Seer Medical's at-home monitoring technology addresses a critical need for accessible, long-term epilepsy diagnostics. The company plans to return to the US market in 2026.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial